Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  
The following IPOs are expected to price this week:

Epizyme (NASDAQ:EPZM), a biotech developing therapeutics for patients with genetically defined cancers, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Epizyme would command a market value of $375 million. Epizyme, which was founded in 2007, booked $48 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol EPZM. Citi (NYSE:C), Cowen & Company and Leerink Swann are the joint bookrunners on the deal.

Kamada (NASDAQ:KMDA), which provides plasma-derived protein therapeutics mostly in Israel and the US, plans to raise $60 million by offering 5.6 million shares at a price range of $10.81 to $10.81. At the midpoint of the proposed range, Kamada would command a market value of $379 million. Kamada, which was founded in 1990, booked $66 million in sales over the last 12 months. The Ness Ziona, Israel-based company plans to list on the NASDAQ under the symbol KMDA. Morgan Stanley (NYSE:MS) and Jefferies & Co. are the joint bookrunners on the deal. Please note: Shares already listed on the Tel Aviv Stock Exchange under the symbol KMDA.

Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.

Last week, there were 6 IPO pricings. ChannelAdvisor (NYSE:ECOM), which provides e-commerce platform to manage sales across multiple online channels, was the week's winner, ending up 34% from its IPO price.
Source: 2 U.S. IPOs Planned For The Week Of May 27